FRIDAY, JUNE 21. Epidemiology/ Genetics. Symposium The Big Picture Genetic Architecture of Diabetes Room S 103 B
|
|
- Ashley Mathews
- 5 years ago
- Views:
Transcription
1 Registration Hours: 9:00 a.m. 6:30 p.m. Shop Store Hours: 9:00 a.m. 6:30 p.m. FRIDAY, JUNE 21 Noon 12:40 p.m. Meet the Expert Sessions 12:50 p.m. 1:30 p.m. Meet the Expert Sessions 2:00 p.m. 4:00 p.m. The Kidney s Unholy Triad Obesity, Hypertension, and Hyperglycemia The Spectrum of Gluten-Related Disorders A Dual Challenge in Maximizing Cost- Effectiveness of Prevention and Treatment Practical Strategies in Older Adults The Big Picture Genetic Architecture of The Brain and the Periphery What s New in In Vivo Study Methods? Informatics, Biomarkers, and Imaging Beta Cell Failure in Type 1 Cause or Consequence? 4:15 p.m. 6:15 p.m. Inflammation, Cardiovascular Disease, and New Findings from Controlled Behavioral Interventions The Effect of Low Testosterone on Glycemic Control and Health in and Obesity The Journey to a Viable Artificial Pancreas Joint ADA/JDRF Global Epidemiology of Type 1 and Implications for Public Health Novel Metabolic Mediators of Energy Homeostasis Hypothalamic Inflammation and Metabolic Disturbance Preclinical Macronutrients, Muscle, and Other Hormones Development and Postnatal Growth of Islets ADA President s Oral Session I 8:00 p.m. 10:00 p.m. Opening Reception The Field Museum (Ticketed Event)
2 Registration Hours: 7:30 a.m. 6:30 p.m. Shop Store Hours: 7:30 a.m. 6:15 p.m. SATURDAY, JUNE 22 Exhibit Hall Hours: 10:00 a.m. 4:00 p.m. Poster Hall Hours: 10:00 a.m. 6:00 p.m. 8:00 a.m. 10:00 a.m. Hypoglycemia in Clinical Practice The Broad Spectrum of Diabetic Neuropathies from Cell Culture to Man 1:45 p.m. 3:45 p.m. Osteomyelitis in the Diabetic Foot Emerging Issues in Diabetic Nephropathy Risks, Mechanisms, and Treatment 4:00 p.m. 6:00 p.m. New Insights Into Treatment of Diabetic Retinopathy and Other The Burden of Diabetic Foot Disease (With Roger Pecoraro Award Lecture) ADA Education Recognition Program Making a Case for Education The Use of a National Education Database Exercise Mechanisms of Action Should Sulfonylureas Remain an Acceptable First-Line Add-On Therapy to Metformin? New Therapeutic Targets in Type 2 Mellitus ADA Care GLP-1 Agonists in Practice Gestational Management and Effects on Offspring (With Norbert Freinkel Award Lecture) Obesity-Related and Other Novel Predictors of Clinical Trials of T-Cell for Reversing Type 1 Insulin Action in Unexpected Sites 10:15 a.m. 11:15 a.m. President, Health Care & Education Address and Outstanding Educator in Award Lecture W 375 A 11:30 a.m. 1:30 p.m. General Poster Session/Guided Audio Poster Tours Hall F1 Noon 1:15 p.m. Professional Section Interest Group Discussions Education What Matters? Behavioral Science Contributions to Understanding (With Richard R. Rubin Award Lecture) The Future of Exercise Mimetics New Insights Into Mechanisms of Exercise Behavioral Interventions for Evidence From Recent Intervention Studies Continuous Glucose Monitoring (CGM) in the Management of in Pregnancy Pharmacologic Management of Obesity Novel The Future Is Now Changing Health Care Delivery Models In Utero and Beyond Insulin Resistance, Puberty, and Pregnancy in Pediatric China Medical Tribune Updating Research in China From Bench to Real World DCCT/EDIC 30th Anniversary Contributions and Progress Pediatric and Young Adult Implications for Metabolic Health in Later Life Genome-Wide Association Study and Beyond Transplant Therapies for Type 1 Current, Emerging, and Novel Islet for the Treatment of Type 1 6:15 p.m. 7:30 p.m. Networking Reception Central Concourse Level 3 (West Building) Mechanisms of Nutrient Stress Fat The White and the Brown Clock Genes in Homeostasis and Disease The Good, the Bad, and the Brown Fat Joint ADA/EASD Metabolic Effects of Bariatric Surgery How Low Can You Go? Improving Glucose With Bariatric Surgery Mechanisms of Action Neural Regulation of Glucose Fetal Programming of Beta Cell Function and Mass Lipid Signaling in the Beta Cell New Insights Into Islet Inflammation
3 Registration Hours: 7:30 a.m. 5:00 p.m. Shop Store Hours: 7:30 a.m. 6:45 p.m. SUNDAY, JUNE 23 WEAR RED TO STOP DIABETES Exhibit Hall Hours: 10:00 a.m. 4:00 p.m. Poster Hall Hours: 7:30 a.m. 6:30 p.m. 8:00 a.m. 10:00 a.m. Small Fiber Dysfunction in the Natural History of Diabetic Neuropathies in Type 1 and Type 2 From the Bench to the Bedside Advances in the Pathogenesis and Treatment of Diabetic Retinopathy A Brave New World Self-Management Support in the Community From Nutrients to Meals How Food Affects Control Applying New Technologies to Advance the Study of Maternal-Infant Outcomes in Obese and Diabetic Women and the Bones Closing the Communication Loop Technology Update in Pediatric Epidemiology of Risk Factors and in Special Populations Islet Autotransplantation Following Total Pancreatectomy for Chronic Pancreatitis State-of-the-Art Hematopoietic Cells and Insulin Action Gastrointestinal Regulation of Glucose Beta Cell Signal Transduction 2:15 p.m. 4:15 p.m. Oh, My Aching Feet Painful Diabetic Neuropathy of the Feet Cellular Mechanisms of Cardiovascular Disease in (With Edwin Bierman Award Lecture) Updates and Applications of Continuous Glucose Monitoring 10:15 a.m. 11:45 a.m. President, Medicine & Science Address and Banting Medal for Scientific Achievement Award Lecture W 375 A E Noon 2:00 p.m. General Poster Session/Guided Audio Poster Tours Hall F1 12:30 p.m. 1:45 p.m. Professional Section Interest Group Discussions Dietary Sweeteners Research, Recommendations, and the Real World Exercise as Adjunct Therapy for Insulin Sensitivity and NDEP New Science Implications for Care Quality Care Measures Can Unfavorably Impact Individual Care Update on New Insulin Preparations for the Management of Improving Health Care Delivery Kelly West Award for Outstanding Achievement in Epidemiology Lecture (2:15 p.m. 3:00 p.m.) Novel Disease Markers in Type 1 GLUT4 and Insulin Signaling Sleep, Circadian Rhythm, and Metabolic Consequences Phenotyping the Engineered Beta Cell Navigating the Spectrum Obesity, Insulin Resistance, and Type 2 in Youth
4 SUNDAY, JUNE 23 (continued) 4:30 p.m. 6:30 p.m. Novel Insights Into Diabetic Cardiomyopathy Hypoglycemia Novel Concepts Education Recharged and Technology Sleep A Novel Behavioral Target in? Persistent Microalbuminuria as an Adequate Indication of Renin-Angiotensin- Aldosterone System (RAAS) Blocking Therapies Non-Glycemic Effects of Incretin-Based Therapy Glucagon- Like Peptide-1 (GLP- 1) and Dipeptidyl Peptidase-4 (DPP-4) Environmental Risk Factors for Type 2 Epidemiologic and Mechanistic Evidence Human Immunology in Clinical Trials NAD Biology and Energy Regulation Role of the Brainstem in Regulation The Failing Beta Cell in Type 2 Joint ADA/AACC Newer Biomarkers in Do They Add Value? On the Horizon Selective Sodium Glucose Co-Transporter Inhibition
5 6:30 a.m. 7:30 a.m. Registration Hours: 7:30 a.m. 4:00 p.m. Shop Store Hours: 7:30 a.m. 6:45 p.m. MONDAY, JUNE 24 Exhibit Hall Hours: 10:00 a.m. 2:00 p.m. Poster Hall Hours: 7:30 a.m. 2:00 p.m. 8:00 a.m 10:00 a.m. So Your Patient Has Diabetic Kidney Disease Now What? Hypoglycemia Mechanisms and Clinical Aspects 2:15 p.m. 4:15 p.m. Joint ADA/ASN From Mice to Men and Back in Diabetic Kidney Disease Mealtime Insulin Dosing It s More Than Counting Carbohydrates Moving Toward a Cure in Type 1 Cost-Effective Health Care/Economics Fats and the Fetus Epidemiology of and Mortality The Anti-Islet Immune Response Mitochondrial Metabolic Functions Beyond OXPHOS Inflammation in Tissue 10:15 a.m. 11:45 a.m. National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture W 375 A E Noon 2:00 p.m. General Poster Session/Guided Audio Poster Tours Hall F1 12:30 p.m. 1:45 p.m. Professional Section Interest Group Discussions Diabetic Dyslipidemia What Influences Patients Risk Perception and Decision Making for Prevention and Control? In a Patient Who Is Failing Oral Antidiabetic Agent Therapy, the Next Step Is To? Nonprescription Therapies for Mellitus The Broad Spectrum of Education Strategies for Delivery Metabolically Healthy Obesity (MHO) and Metabolically Obese Normal Weight (MONW) New Insights and Advances Applications of Exome and Whole Genome Sequencing Lipotoxicity and Insulin Resistance Truth or Consequence? (Animals) Hepatic and Islet Function Electrical Activity and Pathways to Beta Cell Apoptosis Inpatient Management of 4:30 p.m. 6:30 p.m. Managing the Less Common Lipid Disorders Macrovascular Disease in Clinical Studies Intensifying Therapy Using Technology and Teams Update on in Pregnancy in Women With Pre-Existing Primary Results of the Look AHEAD Randomized Controlled Trial of a Lifestyle Intervention in Overweight and Obese Individuals With Type 2 Current Concepts in Nutritional Epidemiology and Metabolic Risk Islet Autotransplantation for the Prevention of Surgical New Mediators of Inter- Organ Metabolic Cross Talk Postprandial Hot Topics Stimulus-Secretion Coupling and Emerging Evidence in Pediatric Type 1
6 Registration Hours: 7:30 a.m. 10:30 a.m. Shop Store Hours: 7:30 a.m. 12:30 p.m. TUESDAY, JUNE 25 8:00 a.m. 10:00 a.m. Defective Hypoglycemia Counterregulation in Mellitus Mechanisms, Prevention, and Reversal Keeping Weight Off Does Diet Macronutrient Composition Matter? Pros and Carbs Exercise and Lipid Obesity Management for the Practicing Clinician New Information on DPP-4 Inhibition Milking the Genome-Wide Association Study (GWAS) Practical Applications for Metabolic Disease Bugs Inside and Out MicroRNA in Regulation Engineering a Beta Cell A Road Map 10:15 a.m. 12:15 p.m. Current State of Insulin Pump Therapy ADA President s Oral Session II
Immunology/ Transplantation. Epidemiology/ Genetics. Mini-Symposium The Future Face of Diabetes Care Beta- Cell Replacement vs. Technology Room: 24
FRIDAY, JUNE 9 Registration Hours: 9:00 a.m.-6:30 p.m. Shop Store Hours: 9:00 a.m.-6:30 p.m. Clinical / 11:30 a.m.- 12:30 p.m. Mini- Clinical Innovation in Vision Mini- Exercise for Type 1 The Stigma of
More informationEpidemiology/ Genetics. Immunology/ Transplantation
FRIDAY, JUNE 7 Registration Hours: 9:00 a.m.-6:30 p.m. Shop Store Hours: 9:00 a.m.-6:30 p.m. 12:30 p.m. Opioids, Cannabinoids, and Other Potentially Addictive Therapies in Painful Diabetic Neuropathy Hypoglycemia
More informationImmunology/ Transplantation. Epidemiology/ Genetics
FRIDAY, JUNE 22, 2018 Registration Hours: 9:00 a.m. 6:30 p.m. Shop Store Hours: 9:00 a.m. 6:30 p.m. 11:30 a.m. 12:30 p.m. Mini- Measuring Neuropathy Is Corneal Confocal Microscopy Ready for Prime Time?
More informationEXPERIENCE NEW HORIZONS IN DIABETES PRELIMINARY PROGRAM. scientificsessions.diabetes.org
EXPERIENCE NEW HORIZONS IN DIABETES PRELIMINARY PROGRAM scientificsessions.diabetes.org ABOUT THE MEETING The American Diabetes Association s Scientific Sessions offers researchers and health care professionals
More informationSubject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119
Acarbose, diabetes prevention trials 32, 33, 40 42 Accelerator hypothesis accelerators beta cell autoimmunity 140, 141, 147, 150, 151 insulin resistance 140, 142 144, 150 obesity 145 148 diabetes risk
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationAmerican Diabetes Association Scientific Sessions Poster Presentation Guidelines. Table of Contents
American Diabetes Association Scientific Sessions Poster Presentation Guidelines Table of Contents Overview.... Page 2 Poster Display Guidelines...Page 2 Poster Design and Development....Pages 2-3 Prior
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationAmerican Diabetes Association Scientific Sessions Poster Presentation and Moderated Poster Discussion eposter Theater Guidelines.
American Diabetes Association Scientific Sessions Poster Presentation and Moderated Poster Discussion eposter Theater Guidelines Table of Contents Overview.............Page 2 Poster Display Guidelines...Page
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDiabetes Complications Recognition and Treatment
Diabetes Complications Recognition and Treatment Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Diabetes is the most difficult of all
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationMetabolic Syndrome: What s so big about BIG?
Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationPathogenesis of Diabetes Mellitus
Pathogenesis of Diabetes Mellitus Young-Bum Kim, Ph.D. Associate Professor of Medicine Harvard Medical School Definition of Diabetes Mellitus a group of metabolic diseases characterized by hyperglycemia
More informationImproving Diabetes Research: Moving Beyond Animal Models. Charu Chandrasekera, Ph.D. Anne Bunner, Ph.D.
Improving Diabetes Research: Moving Beyond Animal Models Charu Chandrasekera, Ph.D. Anne Bunner, Ph.D. July 19, 2014 From Bench-to-Bedside Sulfonylurea Biguanide Dipeptidyl peptidase-4 inhibitor Glucagon-like
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationWeek 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD
Week 3, Lecture 5a Pathophysiology of Diabetes Simin Liu, MD, ScD General Model of Peptide Hormone Action Hormone Plasma Membrane Activated Nucleus Cellular Trafficking Enzymes Inhibited Receptor Effector
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationMaximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE
Maximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE Heavy Numbers Surgeon General report: 68% of adults in U. S. are overweight or obese
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationChapter 37: Exercise Prescription in Patients with Diabetes
Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationComplete Comprehensive Diabetes Educator modules available at CCCEP File #: I-P (Expires: Mar.
CDE Preparation Program Topics (Accredited by CCCEP for 0.5 CEUs/Module section Total = 20 CEUs) Module 1 Pathophysiology of Diabetes 5 segments Module 2 Diabetes and Nutrition 5 segments Module 3 Medications
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationCommon Diabetes-related Terms
Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPersonalized therapeutics in diabetes
Personalized therapeutics in diabetes Leen M. t Hart Molecular Cell Biology & Molecular Epidemiology Leiden University Medical Center Epidemiology & Biostatistics VU University Medical Center Diabetes
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationWhat is Metabolic About Metabolic Surgery? The New ADA Recommendations
What is Metabolic About Metabolic Surgery? The New ADA Recommendations Obesity Symposium September 16, 2017 Timothy Howland, MD Lourdes Endocrinology Bariatric from the Greek root bar- ("weight" as in
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationRole of Academia In Achieving Targets in Diabetes Care
Role of Academia In Achieving Targets in Diabetes Care Disclosures Member of NovoNordisk, Lilly, Metavention, Sanofi, and Janssen Diabetes Advisory Boards Role of Academia in Discovering New Treatments
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationMary ET Boyle, Ph. D. Department of Cognitive Science UCSD
Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Is obesity a brain disorder? What is the evidence to support obesity is a brain disorder? Environmental, biological, and behavioral issues Over
More informationExercise and Type 1 Diabetes
Exercise and Type 1 Diabetes QuickTime and a decompressor are needed to see this picture. 1 Characteristics of Type 1 & Type 2 Diabetes Mellitus ACE Mtng 2011 Rate of New Cases of Type 1 & Type 2 Diabetes
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationThursday 25 October. Hall A
Thursday 25 October Hall A 14:00-15:15 : Neuropathy Diabetic neuropathy: Newer insights into pathogenesis and management Can we prevent diabetic neuropathy? Motor neuropathy: A neglected complication of
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationDR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS
DR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS DIABETETES UPDATE 2015 AIMS OF THE SEMINAR Diagnosis Investigation Management When to refer
More informationChapter 24 Diabetes Mellitus
Chapter 24 Diabetes Mellitus Classification of Diabetes Mellitus Acute Effects of Diabetes Mellitus Chronic Complications of Diabetes Mellitus: Early Stages Chronic Complications of Diabetes Mellitus:
More informationDiabetes in Pregnancy
Disclosure Diabetes in Pregnancy I have no conflicts of interest to disclose Jennifer Krupp, MD Maternal Fetal Medicine St. Marys Hospital/SSM Health Madison, WI Objectives Classification of Diabetes Classifications
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationHormonal Regulations Of Glucose Metabolism & DM
Hormonal Regulations Of Glucose Metabolism & DM What Hormones Regulate Metabolism? What Hormones Regulate Metabolism? Insulin Glucagon Thyroid hormones Cortisol Epinephrine Most regulation occurs in order
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationBreaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes
Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationDiabetes Mellitus. Diabetes Mellitus. Insulin. Glucose. Classifications of DM. Other glucose regulating Hormones
Diabetes Mellitus Diabetes Mellitus Pathophysiology Literally sweet urine Defined by excess blood serum glucose Normally all glucose in the PCT is reabsorbed by active transport When blood glucose is elevated,
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population
More informationDay at a Glance Schedule Saturday, April 22, 2017 Nutrition Across. Nutritional Nutrition
American Society for Scientific Sessions at EB 2017 Day at a Glance Schedule Friday, April 21, 2017 All functions will be held at the McCormick Place Convention Center unless otherwise indicated. Updated
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationFrom 1552 BC to 2015:
From 1552 BC to 2015: How Science Made Diabetes Treatable Mary Gearing Biological and Biomedical Sciences Program, Harvard University Outline 1. A (Very!) Short History of Diabetes 2. Diabetes Research
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationMANAGED CARE DIGEST SERIES FLHCC FLORIDA TYPE 2 DIABETES REPORT th Edition. With a Focus on How Co-Occurring Conditions Impact Diabetes Care
MANAGED CARE SINCE FLHCC FLORIDA TYPE 2 DIABETES REPORT 2 018 6th Edition With a Focus on How Co-Occurring Conditions Impact Diabetes Care 1987 DIGEST SERIES FLHCC FLORIDA TYPE 2 DIABETES REPORT INTRODUCTION
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationDiabetes: Across the Lifespan Friday, October 17, Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children.
Diabetes: Across the Lifespan Friday, October 17, 2014 Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children. Don P. Wilson, M.D., FNLA Diplomate, Am Brd of Clinical Lipidology
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationMetabolic Programming. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD
Metabolic Programming Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD nutritional stress/stimuli organogenesis of target tissues early period critical window consequence of stress/stimuli are
More informationWhy do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?
What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action
More informationThe session was open with an introductory session by Asian Society of continuing Medical Education and followed by the scientific agenda.
3 rd April 2016, Royal Plaza, New Delhi, India "Dia League was held at The Royal Plaza, 19, Ashoka Road, New Delhi - 110 001, India. It was organized by of Asian Society of Continuing Medical Education.
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationDiabetes Pathophysiology and Treatment Strategies
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Diabetes Pathophysiology and Treatment Strategies Beth Careyva MD Lehigh Valley Health Network, beth_a.careyva@lvhn.org Follow
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDiabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018
Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018 Title of My Talk Ancient Times Diabetes has been affecting lives for thousands of years. Egyptians in
More informationCombining Complex Pathophysiologic Concepts: Diabetes Mellitus
Chapter 18 Combining Complex Pathophysiologic Concepts: Diabetes Mellitus KEY TERMS dawn phenomenon diabetes mellitus endocrine pancreas exocrine pancreas hyperglycemia hyperketonemia hypoglycemia insulin
More informationPatient Education Handouts Table of Contents 2013 General Diabetes Information Monitoring and Management
Patient Education Handouts Table of Contents 2013 We have highlighted some handouts that may be helpful for the new patient. Select the ones that are most useful to you. Avoid overwhelming the patient
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adolescents, increase in type 2 diabetes in, 480 Albuminuria, and neuropathy, exercise in, 435 Arterial disease, peripheral, tests for, to assess
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationPreliminary Program Outline
Saturday, June 2, 2018 1:00 pm 5:30 pm Pre-Meeting Symposia Advanced Immunology Basic Science for the Clinician The Immunology of Kidney Transplantation Transplant Center QAPI and Advanced Leadership:
More informationHistory of Investigation
Acini - Pancreatic juice (1º) (2º) Secretions- neuronal and hormonal mechanisms 1) Secretin - bicarbonate rich 2) Cholecystokinin - enzyme rich Islets of Langerhans (contain 4 cell types) Alpha cells (α)-
More informationType Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing?
Type Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing? Dr Bryan Betty Deputy Medical Director PHARMAC GP Cannons Creek, East Porirua Type 2 Diabetes in NZ: The Numbers 250,000
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDiabetes Mellitus. Disclaimer. Multimedia Health Education
Disclaimer This movie is an educational resource only and should not be used to manage Diabetes or blood sugar control.all decisions about management of diabetes must be made in conjunction with your Physician
More information